These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 38015710)

  • 21. Identification and validation of an immune signature associated with EMT and metabolic reprogramming for predicting prognosis and drug response in bladder cancer.
    Zhang Z; Yu Y; Li P; Wang M; Jiao W; Liang Y; Niu H
    Front Immunol; 2022; 13():954616. PubMed ID: 35958586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and validation of a model based on immunogenic cell death related genes to predict the prognosis and immune response to bladder urothelial carcinoma.
    Chen L; Lin J; Wen Y; Chen Y; Chen CB
    Front Oncol; 2023; 13():1291720. PubMed ID: 38023241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer.
    Tan Z; Fu S; Zuo J; Wang J; Wang H
    Aging (Albany NY); 2023 Aug; 15(16):8384-8407. PubMed ID: 37632832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of clinical prognostic factors and analysis of ferroptosis-related gene signatures in the bladder cancer immune microenvironment.
    Ma J; Hu J; Zhao L; Wu Z; Li R; Deng W
    BMC Urol; 2024 Jan; 24(1):6. PubMed ID: 38172792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of an inflammation-related risk signature for prognosis and immunotherapeutic response prediction in bladder cancer.
    Wang Y; Tang Y; Liu Z; Tan X; Zou Y; Luo S; Yao K
    Sci Rep; 2024 Jan; 14(1):1216. PubMed ID: 38216619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer.
    Cai Y; Cheng Y; Wang Z; Li L; Qian Z; Xia W; Yu W
    BMC Cancer; 2023 Aug; 23(1):725. PubMed ID: 37543645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
    Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J
    J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple programmed cell death patterns and immune landscapes in bladder cancer: Evidence based on machine learning and multi-cohorts.
    Li Z; Li Y; Liu L; Zhang C; Li X
    Environ Toxicol; 2024 Mar; 39(3):1780-1801. PubMed ID: 38064272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel signature constructed by mitochondrial function and cell death-related gene for the prediction of prognosis in bladder cancer.
    Yan Z; Liu Y; Wang M; Wang L; Chen Z; Liu X
    Sci Rep; 2024 Jun; 14(1):14667. PubMed ID: 38918587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a prognostic model to predict BLCA based on anoikis-related gene signature: preliminary findings.
    Zhu S; Zhao Q; Fan Y; Tang C
    BMC Urol; 2023 Dec; 23(1):199. PubMed ID: 38049825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
    Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
    BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive Analysis Identified ETV7 as a Potential Prognostic Biomarker in Bladder Cancer.
    Li H; Zhang Y; Zheng S
    Biomed Res Int; 2021; 2021():8530186. PubMed ID: 34926692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PVT1 is a prognostic marker associated with immune invasion of bladder urothelial carcinoma.
    Li P; Qiao G; Lu J; Ji W; Gao C; Qi F
    Math Biosci Eng; 2022 Jan; 19(1):169-190. PubMed ID: 34902986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance and potential regulatory mechanism of overexpression of pituitary tumor-transforming gene transcription factor in bladder cancer.
    Li JD; Farah AA; Huang ZG; Zhai GQ; Wang RG; Liu JL; Wang QJ; Zhang GL; Lei ZL; Dang YW; Li SH
    BMC Cancer; 2022 Jun; 22(1):713. PubMed ID: 35768832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An immune biomarker associated with EMT serves as a predictor for prognosis and drug response in bladder cancer.
    Jiang Y; Yu Z; Zheng H; Zhou X; Zhou M; Geng X; Zhu Y; Huang S; Gong Y; Guo L
    Aging (Albany NY); 2024 Jul; 16(13):10813-10831. PubMed ID: 38980253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a prognostic index and screening of prognosis related genes based on an immunogenomic landscape analysis of bladder cancer.
    Qu G; Liu Z; Yang G; Xu Y; Xiang M; Tang C
    Aging (Albany NY); 2021 Apr; 13(8):12099-12112. PubMed ID: 33888644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a propionate metabolism-related gene-based molecular subtypes and scoring system for predicting prognosis in bladder cancer.
    Zheng F; Wang Z; Li S; Xiong S; Yuan Y; Zeng J; Tan Y; Liu X; Xu S; Fu B
    Eur J Med Res; 2024 Jul; 29(1):393. PubMed ID: 39075554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive Investigation of Genes Associated with Cell Cycle Pathways for Prognosis and Immunotherapy in Bladder Urothelial Carcinoma.
    Mi Y; Wang X
    J Environ Pathol Toxicol Oncol; 2022; 41(3):1-12. PubMed ID: 35993952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.